Brokerages expect that Fibrocell Science Inc (NASDAQ:FCSC) will report earnings per share of ($0.42) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Fibrocell Science’s earnings. Fibrocell Science reported earnings per share of ($1.55) during the same quarter last year, which suggests a positive year-over-year growth rate of 72.9%. The company is expected to announce its next quarterly earnings results on Wednesday, August 8th.
On average, analysts expect that Fibrocell Science will report full-year earnings of ($1.83) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the business will post earnings of ($1.91) per share. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Fibrocell Science.
Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings results on Thursday, May 10th. The company reported ($0.55) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.85) by $0.30.
Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Fibrocell Science in a report on Tuesday, June 5th. ValuEngine upgraded Fibrocell Science from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Zacks Investment Research upgraded Fibrocell Science from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a report on Tuesday, May 15th. Finally, Griffin Securities restated a “buy” rating on shares of Fibrocell Science in a report on Monday, April 2nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $20.25.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asset Management L.P. lifted its holdings in Fibrocell Science by 100.0% in the 1st quarter. Point72 Asset Management L.P. now owns 400,000 shares of the company’s stock worth $236,000 after purchasing an additional 200,000 shares during the last quarter. Anson Funds Management LP acquired a new stake in Fibrocell Science in the 4th quarter worth approximately $287,000. Armistice Capital LLC acquired a new stake in Fibrocell Science in the 4th quarter worth approximately $393,000. Finally, Sabby Management LLC acquired a new stake in Fibrocell Science in the 4th quarter worth approximately $733,000.
Shares of Fibrocell Science traded down $0.12, hitting $2.71, during trading hours on Friday, according to Marketbeat. The stock had a trading volume of 202,921 shares, compared to its average volume of 736,339. The stock has a market cap of $15.34 million, a price-to-earnings ratio of -0.33 and a beta of 0.38. Fibrocell Science has a 52 week low of $2.21 and a 52 week high of $20.85.
Fibrocell Science Company Profile
Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.